Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

ZIOPTAN

×

Overview

What is ZIOPTAN?

Tafluprost is a fluorinated analog of prostaglandin F2α. The chemical name for tafluprost is 1-methylethyl ()-7-{(, , , )-2-[()-3,3-difluoro-4-phenoxy-1-butenyl}-3,5-dihydroxycyclopentyl]-5-heptenoate. The molecular formula of tafluprost is CHFO and its molecular weight is 452.53.

Its structural formula is:

Tafluprost is a colorless to light yellow viscous liquid that is practically insoluble in water.

ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is supplied as a sterile solution of tafluprost with a pH range of 5.5 to 6.7 and an Osmolality range of 260 to 300 mOsmo/kg.

ZIOPTAN contains Active: tafluprost 0.015 mg/mL; Inactives: glycerol, sodium dihydrogen phosphate dihydrate, disodium edetate, polysorbate 80, hydrochloric acid and/or sodium hydroxide (to adjust pH) and Water for Injection.

ZIOPTAN does not contain a preservative.



What does ZIOPTAN look like?



What are the available doses of ZIOPTAN?

Ophthalmic solution containing tafluprost 0.015 mg/mL.

What should I talk to my health care provider before I take ZIOPTAN?

How should I use ZIOPTAN?

ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The recommended dose is one drop of ZIOPTAN in the conjunctival sac of the affected eye(s) once daily in the evening.

The dose should not exceed once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect.

Reduction of the intraocular pressure starts approximately 2 to 4 hours after the first administration with the maximum effect reached after 12 hours.

ZIOPTAN may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is being used, each one should be administered at least 5 minutes apart.

The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration.


What interacts with ZIOPTAN?

Sorry No Records found


What are the warnings of ZIOPTAN?

Sorry No Records found


What are the precautions of ZIOPTAN?

Sorry No Records found


What are the side effects of ZIOPTAN?

Sorry No records found


What should I look out for while using ZIOPTAN?

None.


What might happen if I take too much ZIOPTAN?

Sorry No Records found


How should I store and handle ZIOPTAN?

Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 Storage:Revised: 10/2013© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.® marks owned by Allergan, Inc.Patented. See: www.allergan.com/products/patent_noticesMade in the U.S.A. Array71654PY10 ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is supplied as a sterile solution in translucent low density polyethylene single-use containers packaged in foil pouches (10 single-use containers per pouch). Each single-use container has 0.3 mL solution corresponding to 0.0045 mg tafluprost. NDC 17478-609-30; Unit-of-Use Carton of 30.NDC 17478-609-90; Unit-of-Use Carton of 90. ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is supplied as a sterile solution in translucent low density polyethylene single-use containers packaged in foil pouches (10 single-use containers per pouch). Each single-use container has 0.3 mL solution corresponding to 0.0045 mg tafluprost. NDC 17478-609-30; Unit-of-Use Carton of 30.NDC 17478-609-90; Unit-of-Use Carton of 90.